Additional Information (definitive) (defa14c)
October 13 2020 - 9:03AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
SCHEDULE
14C INFORMATION
Information
Statement Pursuant to Section 14(c)
of
the Securities Exchange Act of 1934
Check
the appropriate box:
☐
|
Preliminary Information
Statement
|
|
|
☐
|
Confidential, for
Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
|
|
|
☐
|
Definitive Information
Statement
|
|
|
☒
|
Definitive Additional
Materials
|
YEW
BIO-PHARM GROUP, INC.
(Name
of Registrant as Specified In Its Charter)
Payment
of Filing Fee (Check the appropriate box):
☒
|
No
fee required.
|
|
|
☐
|
Fee computed on
table below per Exchange Act Rules 14c-5(g) and 0-11.
|
|
1)
|
Title
of each class of securities to which transaction applies:
|
|
2)
|
Aggregate
number of securities to which transaction applies:
|
|
3)
|
Per
unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which
the filing fee is calculated and state how it was determined):
|
|
4)
|
Proposed
maximum aggregate value of transaction:
|
☐
|
Fee
paid previously with preliminary materials.
|
|
|
☐
|
Check
box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting
fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date
of its filing.
|
|
1)
|
Amount
Previously Paid:
|
|
2)
|
Form,
Schedule or Registration Statement No.:
|
YEW
BIO-PHARM GROUP, INC.
9460
Telstar Avenue, Suite 6
El
Monte, California 91731
NOTICE
OF INTERNET AVAILABILITY OF INFORMATION STATEMENT MATERIALS
AND
FORM
10-K FOR THE YEAR 2019
To
Our Stockholders:
An
Information Statement is being made available by the Board of Directors of Yew Bio-Pharm Group, Inc., a Nevada corporation (the
“Company”), to holders of record of the Company’s common stock at the close of business on September 28, 2020
(the “Record Date”). The purpose of this Information Statement is to inform the Company stockholders of the following
actions taken by written consent of the holders of a majority of the Company’s voting stock, dated September 28, 2020:
|
1.
|
To
elect seven (7) directors to serve until the next Annual Meeting of Shareholders and thereafter until their successors are elected
and qualified; and
|
|
2.
|
To
grant the Board of Directors the discretionary authority to amend the Company’s articles of incorporation to affect a reverse
stock split (the “Reverse Split Proposal”) of the Company’s common stock (“Common Stock”); and
|
|
3.
|
A
proposal to ratify the appointment of Simon & Edward, LLP as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2020.
|
The
foregoing actions were approved on September 28, 2020 by our Board of Directors. In addition, on September 28, 2020 the holders
of 52.1% of the Company’s outstanding voting securities, as of the Record Date approved the foregoing actions. The number
of shares voting for the proposals was sufficient for approval.
Section
78.320 of the Nevada Revised Statutes (the “NRS”) provides in part that any action required or permitted to be taken
at a meeting of the stockholders may be taken without a meeting if, before or after the action, a written consent thereto is signed
by stockholders holding at least a majority of the voting power, except that if a different proportion of voting power is required
for such an action at a meeting, then that proportion of written consents is required.
Important
Notice Regarding the Availability of Information Statement Materials and the Form 10-K
Pursuant
to Securities and Exchange Commission Rule §240.14C-2, you are receiving this notice that the Information Statement and Annual
report on Form 10-K are available on the Internet. This communication provides only a brief overview of the more complete Information
Statement Materials. We encourage you to access and review all of the important information contained in the Information Statement
Materials.
Follow
the instructions below to view the materials or request printed or email copies.
Our
Information Statement and Annual Report on Form 10-K for the fiscal year ended December 31, 2019, are available at www.yewbiopharm.com/investors/annual-meeting/
If
you want to receive a paper or e-mail copy of these documents, you must request one. There is no charge to you for requesting
a paper or e-mail copy. Please make your request for a copy by one of the following methods on or before October 23, 2020 to facilitate
timely delivery.
|
-
|
E-mail
to hpang@yewbiopharm.com
|
|
-
|
Mail
at Yew Bio-Pharm Group, Inc., 9460 Telstar Avenue, Suite 6, El Monte, CA 91731
|
|
-
|
Telephone
call to (626) 401-9588.
|
WE
ARE NOT ASKING FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.
|
By
Order of the Board of Directors,
|
|
|
|
/s/
Zhiguo Wang
|
|
Zhiguo
Wang, Chief Executive Officer
|
|
Dated:
October 13, 2020
|
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Yew Bio Pharm (CE) (USOTC:YEWB)
Historical Stock Chart
From Sep 2023 to Sep 2024